In conclusion, the prevention and management of chronic allergic diseases require a multifaceted approach, incorporating primary, secondary, and tertiary strategies tailored to individual risk factors and disease progression. Early-life interventions, particularly the timely introduction of allergenic foods, have shown strong evidence in reducing the incidence of food allergies, especially in high-risk infants. Similarly, strategies aimed at minimizing environmental exposures and maintaining the integrity of the skin barrier are central to preventing conditions like atopic dermatitis.
Secondary prevention methods, such as oral and sublingual immunotherapy, have demonstrated success in building tolerance among sensitized individuals and reducing the onset of more severe allergic reactions. Tertiary prevention focuses on sustained disease management through advanced therapies including monoclonal antibodies like omalizumab and dupilumab, which have shown effectiveness in reducing exacerbations and improving quality of life in patients with allergic asthma and eczema.
Emerging approaches, such as gene editing and microbiota-targeted therapies, offer future potential but require further clinical validation. Overall, individualized, evidence-based interventions, alongside ongoing research and surveillance, remain essential for reducing the global burden of allergic diseases and improving long-term outcomes across age groups.
